Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

June 13, 2018
Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

June 12, 2018
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

June 8, 2018
Sage Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

Read More News

Associated Team Members

Kevin Starr
Partner